Eloxatin Adds Adjuvant Colorectal Cancer Claim Based On Disease-Free Survival
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' agent is the first oncologic to be approved for an adjuvant colorectal cancer indication based on a disease-free survival endpoint. It did not demonstrate benefit in overall survival after a median follow-up of four years.
You may also be interested in...
Sanofi’s Eloxatin Gets Survival Label
FDA clears add-on to claims for colorectal cancer drug.
Sanofi’s Eloxatin Gets Survival Label
FDA clears add-on to claims for colorectal cancer drug.
Colon Cancer Adjuvant Therapies Should Show 3-Year Disease-Free Survival, Cmte. Says
Committee members voted unanimously that disease-free survival should be used as a primary endpoint for colon cancer treatment in the adjuvant setting. The committee also voted 8-5 that progression-free survival could be used for first-line therapies.